Feasibility of Tissue Plasminogen Activator Formulated for Pulmonary Delivery
- 22 September 2005
- journal article
- research article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 22 (10) , 1700-1707
Abstract
This study was conducted to assess the feasibility of a pulmonary formulation of tissue plasminogen activator (tPA) for nebulization into the airway by measuring protein stability, biologic activity, particle size, and estimating human lung distribution.Keywords
This publication has 30 references indexed in Scilit:
- Inhibition of human neutrophil reactive oxygen species production and p67phox translocation by cigarette smoke extractAtherosclerosis, 2005
- Encapsulation of insulin–cyclodextrin complex in PLGA microspheres: a new approach for prolonged pulmonary insulin deliveryJournal of Microencapsulation, 2004
- ADMINISTRATION OF EXOGENOUS TISSUE PLASMINOGEN ACTIVATOR REDUCES OEDEMA IN MICE LACKING THE TISSUE PLASMINOGEN ACTIVATOR GENEClinical and Experimental Pharmacology and Physiology, 2004
- Evolving Strategies for Insulin Delivery and TherapyDrugs, 2004
- Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medicationsBritish Journal of Clinical Pharmacology, 2003
- Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medicationsBritish Journal of Clinical Pharmacology, 2003
- Respiratory Deposition Patterns of Salbutamol pMDI with CFC and HFA-134a Formulations in a Human Airway ReplicaJournal of Aerosol Medicine, 2001
- Neutrophil activation and acute lung injuryCurrent Opinion in Critical Care, 2001
- Particle Deposition in a Cast of Human Oral AirwaysAerosol Science and Technology, 1999
- The extinction coefficient of cytochrome cBiochimica et Biophysica Acta, 1962